ROSEMARY GARZA

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R.8528 - PI Post Acute Access Act: This bill allows for separate payment under Medicare to skilled nursing facilities for items and services that are needed to administer intravenous immune globin (IVIG) to patients with primary immune deficiency diseases (rare genetic disorders that impair the immune system and increase vulnerability for other infections). H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R.8528 - PI Post Acute Access Act: This bill allows for separate payment under Medicare to skilled nursing facilities for items and services that are needed to administer intravenous immune globin (IVIG) to patients with primary immune deficiency diseases (rare genetic disorders that impair the immune system and increase vulnerability for other infections). H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R.8528 - PI Post Acute Access Act: This bill allows for separate payment under Medicare to skilled nursing facilities for items and services that are needed to administer intravenous immune globin (IVIG) to patients with primary immune deficiency diseases (rare genetic disorders that impair the immune system and increase vulnerability for other infections). H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R.8528 - PI Post Acute Access Act: This bill allows for separate payment under Medicare to skilled nursing facilities for items and services that are needed to administer intravenous immune globin (IVIG) to patients with primary immune deficiency diseases (rare genetic disorders that impair the immune system and increase vulnerability for other infections). H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R.8528 - PI Post Acute Access Act: This bill allows for separate payment under Medicare to skilled nursing facilities for items and services that are needed to administer intravenous immune globin (IVIG) to patients with primary immune deficiency diseases (rare genetic disorders that impair the immune system and increase vulnerability for other infections). H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

FY2026 Appropriations bill for Health and Human Services; Medicare and Medicaid drug pricing and eligibility H.R. 1, One Big, Beautiful Bill Act; Medicare provisions - Most Favored Nations and drug pricing, Medicaid provisions - PBM Reform and eligibility, R&D tax credits

FY2026 Appropriations bill for Health and Human Services; Medicare and Medicaid drug pricing and eligibility FY2026 Appropriations bill for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies; Blood Safety and Pathogen Reduction H.R. 1, One Big, Beautiful Bill Act; Medicare provisions - Most Favored Nations and drug pricing, Medicaid provisions - PBM Reform and eligibility, R&D tax credits

S. 694 & H.R. 1476, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343, John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

S. 694 & H.R. 1476, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343, John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

S. 694 & H.R. 1476, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343, John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

S. 694 & H.R. 1476, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343, John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

S. 694 & H.R. 1476, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343, John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.

H.R. 6465 & S. 4741, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.

H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.

H.R. 6465 & S. 4741, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.

H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.

H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.

H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.

H.R. 6465, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.

H.R. 6465 & S. 4741, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.

H.R. 6465 & S. 4741, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 5818, Medicare IVIG Access Enhancement Act of 2023. H.R. 4438, John W. Walsh Alpha-1 Home Infusion Act of 2023.